Alghamdi Abdullah S, Alothmani Hammad S, Mogharbel Mohammed, Albiladi Hazeez, Babatin Mohamed
Medical Department/Gastroenterology Unit, King Fahad General Hospital, Jeddah, SAU.
Gastroenterology Unit, King Fahad Hospital, Jeddah, SAU.
Cureus. 2020 Sep 11;12(9):e10380. doi: 10.7759/cureus.10380.
Background Hepatitis B Virus (HBV) continues to be a significant global health problem despite vaccination programs and effective antiviral drugs. Aim Assess tenofovir alafenamide fumarate (TAF) as a new treatment modality in light of the clinical characteristics of HBV patients. Settings and design A real-world observational study Methods and material We collected data of 71 HBV patients and recorded the hepatitis B virus deoxyribonucleic acid (HBV-DNA) plasma levels and biochemistry test results for the alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine levels at three time points, including baseline, time of switching to TAF, and six months after switching. Results From the time of switching to TAF till six months later, HBV-DNA plasma levels significantly decreased from 838.61 IU/mL to 16.7 IU/mL (p-value of <0.05). ALT and AST levels dropped from 29.05 U/L to 27 U/L and from 21.34 U/L to 20.7 U/L (p-values 0.328 and 0.410, respectively). Although TAF did not show a statistically significant reduction in the serum levels of AST, ALT, and creatinine, it showed a detectable maintenance level. Conclusions In the evaluated cohort, all clinical characteristics of HBV were maintained six months after switching patients to TAF.
背景 尽管有疫苗接种计划和有效的抗病毒药物，乙型肝炎病毒（HBV）仍然是一个重大的全球健康问题。目的 根据HBV患者的临床特征，评估富马酸替诺福韦酯（TAF）作为一种新的治疗方式。设置与设计 一项真实世界观察性研究 方法与材料 我们收集了71例HBV患者的数据，并记录了三个时间点（包括基线、转换为TAF时以及转换后六个月）的乙型肝炎病毒脱氧核糖核酸（HBV-DNA）血浆水平以及丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）和血清肌酐水平的生化检测结果。结果 从转换为TAF到六个月后，HBV-DNA血浆水平从838.61 IU/mL显著降至16.7 IU/mL（p值<0.05）。ALT和AST水平分别从29.05 U/L降至27 U/L以及从21.34 U/L降至20.7 U/L（p值分别为0.328和0.410）。虽然TAF在AST、ALT和肌酐的血清水平上未显示出统计学上的显著降低，但显示出可检测的维持水平。结论 在评估队列中，将患者转换为TAF六个月后，HBV的所有临床特征均得以维持。
